The human heart is a muscle, but it’s also a kind of complicated balloon—a balloon that fills and empties roughly 60 to 100 times every minute, and several billion times during the course of a ...

Panel A shows a cross-section of a normal heart (top) and an endomyocardial biopsy sample from a normal heart (bottom; with hematoxylin and eosin staining) that shows normal histologic characteristics ...

Treatment sometimes involves an implantable defibrillator. Hypertrophic cardiomyopathy is the most common form of genetic heart disease worldwide. Researchers have estimated that up to 1 in 200 people ...

Hypertrophic cardiomyopathy (HCM) is the most common genetic heart (cardiac) condition. It affects more than one in 500 people in the US. Genetic counseling and genetic testing can be helpful so you ...

The diagnosis of a potentially lethal cardiovascular disease in a young athlete presents a complex dilemma regarding athlete safety, patient autonomy, team or institutional risk tolerance and medical ...

Hypertrophic cardiomyopathy (HCM) is a progressive heart disease with four stages. At each stage, HCM has a greater impact on the heart’s structure and function. In the earliest stage, a person will ...

Hypertrophic cardiomyopathy is a heart condition where the heart muscle becomes abnormally thick. This makes it harder for the heart to work correctly. Obstructive hypertrophic cardiomyopathy (oHCM) ...

Treating patients with HCM is guided by how severe symptoms are, whether a patient has any risk factors for sudden cardiac death, and whether a patient has cardiac arrhythmias and other associated ...

Beta-blockers have been the initial treatment for symptomatic obstructive hypertrophic cardiomyopathy (HCM) despite limited evidence of their efficacy. Aficamten is a cardiac myosin inhibitor that ...